Characterization of Cerebral Amyloid Deposition With 18F‐Flutemetamol PET and of Glucose Metabolism With 18F‐FDG PET in Individuals Enrolled in the ALFA Project.

Trial Profile

Characterization of Cerebral Amyloid Deposition With 18F‐Flutemetamol PET and of Glucose Metabolism With 18F‐FDG PET in Individuals Enrolled in the ALFA Project.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Fludeoxyglucose F-18 (Primary) ; Flutemetamol-F-18 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Mar 2017 Planned End Date changed from 1 Jun 2019 to 1 Mar 2020.
    • 01 Mar 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Mar 2019.
    • 01 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top